source
- Novartis licenses Abogen’s mRNA CD19×CD3 engager in $575M upfront dealAbogen Biosciences saw its COVID vaccine miss the market, prompting questions about whether its mRNA platform could be leveraged for other therapies. Novartis agreed to pay $575 million up front f…
- Half-century after IL-2 discovery, its impact on HIV, cancer and blood safety is highlightedRobert Gallo marks the 50-year anniversary of the 1976 paper that described interleukin-2, one of the first cytokines identified and essential for T-cell growth. He notes that IL-2 enabled the dis…